IMMUNOCHEMICAL MARKER FOR TUMOR HYPOXIA

肿瘤缺氧的免疫化学标志物

• 批准号: 2545398
• 负责人: JAMES ARTHUR RALEIGH
• 金额: $ 19.63万
• 依托单位: NATURAL PHARMACIA INTERNATIONAL, INC.
• 依托单位国家: 美国
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-03-01 至 1998-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2545398
• 关键词: artificial intelligence; azoles; biomarker; carcinoma; cervix neoplasms; computer assisted diagnosis; computer system design /evaluation; diagnosis design /evaluation; enzyme linked immunosorbent assay; human subject; hypoxia; image processing; immunocytochemistry; monoclonal antibody; neoplasm /cancer immunodiagnosis

Low tissue oxygen concentration or hypoxia occurs with cancer and cardiovascular disease and plays a role in diabetes and alcohol-induced liver disease. Hypoxic tumor cells are important because they resist both radiation and drug treatment. Hyperbaric oxygen, radiosensitizers, hypoxic cell cytotoxins and neutron irradiation are used to get around this resistance but hypoxia is rarely monitored so patients who might benefit are not selected and the reason for success or failure of these costly therapies is not known. The immunostaining, marker method is ideal for measuring tumor hypoxia. The marker is injected into cervix, head and neck and breast cancer patients and biopsy samples taken 24 hours later. Immunostaining of formalin-fixed, tissue sections reveals hypoxia and standard image analysis methods measure its extent. The marker method could be of enormous value in treatment planning for cancer patients and could also be used in animal studies of liver damage, stroke, cardiac arrest, diabetes, etc. PROPOSED COMMERCIAL APPLICATION: Potential commercial applications include routine use in conventional radiation therapy (potential up to 300,000 patients/year in US); in experimental therapies based on hypoxia in human tumors; in experimental models of tumor hypoxia, stroke, cardiac failure, liver disease, wound healing, angiogenesis and normal tissue development.

低组织氧浓度或缺氧是癌症和低氧发生的 心血管疾病并在糖尿病和酒精诱导的 肝病。低氧肿瘤细胞很重要，因为它们都抵抗 辐射和药物治疗。高压氧，放射增敏剂， 低氧细胞细胞毒素和中子辐射用于四处走动 这种抗药性，但缺氧很少受到监测，因此可能 没有选择福利，这些成功或失败的原因 昂贵的疗法尚不清楚。免疫染色，标记方法是理想的 用于测量肿瘤缺氧。 标记被注入子宫颈，头部 以及颈部和乳腺癌患者和活检样本24小时 之后。福尔马林固定，组织切片的免疫染色显示缺氧 和标准图像分析方法衡量其程度。标记方法 对于癌症患者的治疗计划和 也可以用于肝损伤，中风，心脏的动物研究 逮捕，糖尿病等 拟议的商业应用：潜在的商业申请 包括常规放射治疗中的常规使用（潜在 美国/年30万名患者）；在基于缺氧的实验疗法中 在人类肿瘤中；在肿瘤缺氧，中风，心脏的实验模型中 衰竭，肝病，伤口愈合，血管生成和正常组织 发展。

项目成果

Hypoxia and differentiation in squamous cell carcinomas of the uterine cervix: pimonidazole and involucrin.

• 发表时间: 2003-10
• 期刊: Clinical cancer research : an official journal of the American Association for Cancer Research
• 作者: Y. Azuma;S. Chou;R. Lininger;B. Murphy;M. Varia;J. Raleigh

Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia.

• 发表时间: 2005
• 期刊: Clinical cancer research : an official journal of the American Association for Cancer Research
• 作者: M. Arcasoy;K. Amin;S. Chou;Z. Haroon;M. Varia;J. Raleigh

Evidence that involucrin, a marker for differentiation, is oxygen regulated in human squamous cell carcinomas.

• DOI: 10.1038/sj.bjc.6601585
• 发表时间: 2004-02-09
• 期刊: British journal of cancer
• 影响因子: 8.8

A clinical study of hypoxia and metallothionein protein expression in squamous cell carcinomas.

鳞状细胞癌缺氧与金属硫蛋白蛋白表达的临床研究。

• 发表时间: 2000
• 期刊: Clinical cancer research : an official journal of the American Association for Cancer Research.
• 作者: Raleigh,JA;Chou,SC;Calkins-Adams,DP;Ballenger,CA;Novotny,DB;Varia,MA
• 通讯作者: Varia,MA

Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker.

• 发表时间: 1998-09
• 期刊: Cancer research
• 影响因子: 11.2
• 作者: J. Raleigh;Dennise P. Calkins-Adams;L. Rinker;C. A. Ballenger;M. Weissler;W. Fowler;D. Novotny;M. Varia